These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 22439669)

  • 1. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    Hoy SM; Keating GM
    Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rasagiline: a review of its use in the management of Parkinson's disease.
    Oldfield V; Keating GM; Perry CM
    Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasagiline: a guide to its use in Parkinson's disease.
    Keating GM; Lyseng-Williamson KA; Hoy SM
    CNS Drugs; 2012 Sep; 26(9):781-5. PubMed ID: 22834567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
    Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
    Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
    Tolosa E; Stern MB
    Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
    McCormack PL
    CNS Drugs; 2014 Nov; 28(11):1083-97. PubMed ID: 25322951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
    Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
    Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
    Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
    Stocchi F; Rabey JM
    Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.
    Elmer L; Schwid S; Eberly S; Goetz C; Fahn S; Kieburtz K; Oakes D; Blindauer K; Salzman P; Oren S; Prisco UL; Stern M; Shoulson I; ;
    J Neurol Sci; 2006 Oct; 248(1-2):78-83. PubMed ID: 16828804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Nakaya R; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):289-297. PubMed ID: 30635744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
    Zhang L; Zhang Z; Chen Y; Qin X; Zhou H; Zhang C; Sun H; Tang R; Zheng J; Yi L; Deng L; Li J
    Int J Neuropsychopharmacol; 2013 Aug; 16(7):1529-37. PubMed ID: 23551956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
    Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J
    Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of rasagiline in the treatment of Parkinson's disease.
    Leegwater-Kim J; Bortan E
    Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
    Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
    Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.